Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Biomarkers in neonates receiving potential nephrotoxic drugs.

European review for medical and pharmacological sciences

Sridharan K, Al Jufairi M, Al Segai O, Al Ansari E, Hashem Ahmed H, Husain Shaban G, Malalla Z, Al Marzooq R, Al Madhoob A, Saeed Tabbara K.
PMID: 34859872
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7078-7088. doi: 10.26355/eurrev_202111_27260.

OBJECTIVE: Novel biomarkers, such as kidney injury molecule-1 (KIM-1), cystatin, and neutrophil gelatinase-associated lipocalin (NGAL) were shown to predict acute kidney injury (AKI) earlier than serum creatinine in critically ill. We carried out the present study to evaluate these...

Cite
Sridharan K, Al Jufairi M, Al Segai O, et al. Biomarkers in neonates receiving potential nephrotoxic drugs. Eur Rev Med Pharmacol Sci. 2021;25(22):7078-7088doi: 10.26355/eurrev_202111_27260.
Sridharan, K., Al Jufairi, M., Al Segai, O., Al Ansari, E., Hashem Ahmed, H., Husain Shaban, G., Malalla, Z., Al Marzooq, R., Al Madhoob, A., & Saeed Tabbara, K. (2021). Biomarkers in neonates receiving potential nephrotoxic drugs. European review for medical and pharmacological sciences, 25(22), 7078-7088. https://doi.org/10.26355/eurrev_202111_27260
Sridharan, K, et al. "Biomarkers in neonates receiving potential nephrotoxic drugs." European review for medical and pharmacological sciences vol. 25,22 (2021): 7078-7088. doi: https://doi.org/10.26355/eurrev_202111_27260
Sridharan K, Al Jufairi M, Al Segai O, Al Ansari E, Hashem Ahmed H, Husain Shaban G, Malalla Z, Al Marzooq R, Al Madhoob A, Saeed Tabbara K. Biomarkers in neonates receiving potential nephrotoxic drugs. Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7078-7088. doi: 10.26355/eurrev_202111_27260. PMID: 34859872.
Copy Download .nbib Format: NLM
Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study.

Journal of clinical pharmacy and therapeutics

Sridharan K, Al Jufairi M, Al Ansari E, Al Marzooq R, Hubail Z, Hasan SJR, Al Madhoob A.
PMID: 33638909
J Clin Pharm Ther. 2021 Aug;46(4):1010-1019. doi: 10.1111/jcpt.13384. Epub 2021 Feb 27.

WHAT IS KNOWN AND OBJECTIVES: Acetaminophen has been increasingly used in treating patent ductus arteriosus (PDA) in preterm neonates. Variations were observed in the dosing regimen of acetaminophen across the studies. There is hardly any data available for a...

Cite
Sridharan K, Al Jufairi M, Al Ansari E, et al. Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study. J Clin Pharm Ther. 2021;46(4):1010-1019doi: 10.1111/jcpt.13384.
Sridharan, K., Al Jufairi, M., Al Ansari, E., Al Marzooq, R., Hubail, Z., Hasan, S. J. R., & Al Madhoob, A. (2021). Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study. Journal of clinical pharmacy and therapeutics, 46(4), 1010-1019. https://doi.org/10.1111/jcpt.13384
Sridharan, Kannan, et al. "Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study." Journal of clinical pharmacy and therapeutics vol. 46,4 (2021): 1010-1019. doi: https://doi.org/10.1111/jcpt.13384
Sridharan K, Al Jufairi M, Al Ansari E, Al Marzooq R, Hubail Z, Hasan SJR, Al Madhoob A. Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study. J Clin Pharm Ther. 2021 Aug;46(4):1010-1019. doi: 10.1111/jcpt.13384. Epub 2021 Feb 27. PMID: 33638909.
Copy Download .nbib Format: NLM
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus.

Xenobiotica; the fate of foreign compounds in biological systems

Sridharan K, Al Jufairi M, Al Ansari E, Jasim A, Eltayeb Diab D, Al Marzooq R, Al Madhoob A.
PMID: 34529545
Xenobiotica. 2021 Nov;51(11):1335-1342. doi: 10.1080/00498254.2021.1982070. Epub 2021 Sep 28.

Acetaminophen is gaining importance as a first-line drug for treating patent ductus arteriosus (PDA) in neonates. Predominant metabolites of acetaminophen in preterm neonates vary from that of adults; and the drug is predominantly metabolised by conjugation and partly by...

Cite
Sridharan K, Al Jufairi M, Al Ansari E, et al. Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus. Xenobiotica. 2021;51(11):1335-1342doi: 10.1080/00498254.2021.1982070.
Sridharan, K., Al Jufairi, M., Al Ansari, E., Jasim, A., Eltayeb Diab, D., Al Marzooq, R., & Al Madhoob, A. (2021). Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus. Xenobiotica; the fate of foreign compounds in biological systems, 51(11), 1335-1342. https://doi.org/10.1080/00498254.2021.1982070
Sridharan, Kannan, et al. "Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus." Xenobiotica; the fate of foreign compounds in biological systems vol. 51,11 (2021): 1335-1342. doi: https://doi.org/10.1080/00498254.2021.1982070
Sridharan K, Al Jufairi M, Al Ansari E, Jasim A, Eltayeb Diab D, Al Marzooq R, Al Madhoob A. Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus. Xenobiotica. 2021 Nov;51(11):1335-1342. doi: 10.1080/00498254.2021.1982070. Epub 2021 Sep 28. PMID: 34529545.
Copy Download .nbib Format: NLM
Biomarkers in neonates receiving potential nephrotoxic drugs.

European review for medical and pharmacological sciences

Sridharan K, Al Jufairi M, Al Segai O, Al Ansari E, Hashem Ahmed H, Husain Shaban G, Malalla Z, Al Marzooq R, Al Madhoob A, Saeed Tabbara K.
PMID: 34859872
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7078-7088. doi: 10.26355/eurrev_202111_27260.

OBJECTIVE: Novel biomarkers, such as kidney injury molecule-1 (KIM-1), cystatin, and neutrophil gelatinase-associated lipocalin (NGAL) were shown to predict acute kidney injury (AKI) earlier than serum creatinine in critically ill. We carried out the present study to evaluate these...

Cite
Sridharan K, Al Jufairi M, Al Segai O, et al. Biomarkers in neonates receiving potential nephrotoxic drugs. Eur Rev Med Pharmacol Sci. 2021;25(22):7078-7088doi: 10.26355/eurrev_202111_27260.
Sridharan, K., Al Jufairi, M., Al Segai, O., Al Ansari, E., Hashem Ahmed, H., Husain Shaban, G., Malalla, Z., Al Marzooq, R., Al Madhoob, A., & Saeed Tabbara, K. (2021). Biomarkers in neonates receiving potential nephrotoxic drugs. European review for medical and pharmacological sciences, 25(22), 7078-7088. https://doi.org/10.26355/eurrev_202111_27260
Sridharan, K, et al. "Biomarkers in neonates receiving potential nephrotoxic drugs." European review for medical and pharmacological sciences vol. 25,22 (2021): 7078-7088. doi: https://doi.org/10.26355/eurrev_202111_27260
Sridharan K, Al Jufairi M, Al Segai O, Al Ansari E, Hashem Ahmed H, Husain Shaban G, Malalla Z, Al Marzooq R, Al Madhoob A, Saeed Tabbara K. Biomarkers in neonates receiving potential nephrotoxic drugs. Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7078-7088. doi: 10.26355/eurrev_202111_27260. PMID: 34859872.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries